Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Yasons Chemex Care Ltd. (YCCL)
SME CapIndustrials stocks · SME cap · NSE
Yasons Chemex Care Ltd. operates in Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result01 Jun, 08:00 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)
Technical timing lens
Trend score and candlestick chart
29Bearishfull bear SMA stack · SMA20 -13.4% / mo · MACD − · near 52W low
Stock trend: 18
Sector RS: 46
Sector 3M: -7.1% vs Nifty 500 -5.6%
Industrials FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
YCCLD candles · FIT view-21.0%Latest close ₹7.90 on 2026-10-21
Bar
+0.0%
RSI
38
MACD hist
-0.01
52W pos
0%
2026-10-21O ₹7.90H ₹7.90L ₹7.90C ₹7.90Vol 3,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
YCCLNifty India ManufacturingNifty 500
- YCCL
- -21.0%
- Nifty 500
- -5.0%
- Nifty India Manufacturing
- -6.8%
- Vs Nifty 500
- -16.0 pp
Chart stats
21 Oct 2026- From 52W high
- -43.4%
- 52W range position
- 0%
- ATR (14)
- 4.5%
- Volume vs 20D
- 0.30x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹7.9 - ₹9.3
₹14
₹7.9 - ₹14
₹0.4
Latest completed session
20-session average
52.0% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is weak.
Suggested next step
Verify management risk first
Do not let cheap valuation override weak Trust or governance evidence.
U-Score
Legacy · OVERVALUED22
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad22
Revenue +50.0% · PAT NDF YoY
Technical
Bearish29
Price trend and sector-relative-strength timing.
Valuation
Legacy model-815.9%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence49
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 22/100margin compression · Rev +50% YoY
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹47.6 Cr | +50.0% | -3.5% |
| EBITDA | ₹-2.3 Cr | NDF | -234.7% |
| Operating margin | -4.9% | NDF | -841 bps |
| PAT | ₹-0.1 Cr | NDF | -107.8% |
| PAT margin | -0.2% | NDF | -224 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 17.50
- P/B
- 0.40
- EV/EBITDA
- —
- Market Cap
- 16.40Cr
Profitability
- ROE
- 2.29%
- ROCE
- 5.26%
- ROA
- 1.38%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 27.38%
- EPS 5Y
- -27.65%
- Revenue 3Y
- 38.00%
- EPS 3Y
- -35.00%
Balance Sheet
- Debt/Equity
- 0.32
- Interest Coverage
- -0.46×
- Altman Z
- 2.45
- Book Value
- 21.50
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -0.74 Cr
- EPS TTM
- 0.49
Shareholding
- Promoter Hold
- 51.47%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 8%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 47.5-3.5% vs prev
Net Profit
₹ CrLatest: -0.1-107.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend unclear. RSI 38.
- SMA20 falling (~15.4% over last month) — short-term momentum negative.
- RSI(14) at 38 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
18
RS percentile
Stage 4 Downtrend
1M return
-14.6%
3M return
-21.0%
6M return
-35.2%
1Y return
-
RS 1D
+4
RS 20D
-6
Sector rank
#2
Industry rank
#6
Stage evidence
- Price is 24.1% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -5.1%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
159 observations
21 Oct 2026Value 68.54-1.55%
RS vs Nifty 50069
Valuation & peers
U-Score 22 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 22 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation14/30
Growth6/25
Quality0/20
Balance Sheet8/15
Cash Flow0/10
Piotroski
3/9 (+1)
Penalties
-7
Raw sum
22
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
22/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 8/15 to the score.
- Valuation contributes 14/30 to the score.
- Growth contributes 6/25 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Fair-value margin of safety is negative at -815.9%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
17.5
PB
0.4
EV/EBITDA
—
ROE
2.3%
ROCE
5.3%
FCF Yield
—
Debt/Equity
0.3
MoS
-815.9%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
22
Previous: 22
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-815.9%
Previous: -839.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
22
22
22
22
22
22
22
22
22
22
22
22
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹15.4
+48.7% MoS
Growth-justified P/E
1.8
Growth-justified Value
₹0.86
-815.9% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
RITEZONE
SME
Rite Zone Chemcon India Ltd.
Specialty Chemicals
match 160
53
21.2
2.2%
+43%
FAIR VALUE
VSCL
SME
VADIVARHE SPECIALITY CHEMICALS LTD.
Specialty Chemicals
match 160
18
—
—
—
OVERVALUED
MCON
SME
Mcon Rasayan India Ltd.
Specialty Chemicals
match 157
60
9.8
8.8%
+75%
UNDERVALUED
UNILEX
SME
Unilex Colours and Chemicals Ltd.
Specialty Chemicals
match 152
36
5.0
10.4%
+32%
WATCHLIST
SACHEEROME
SME
Sacheerome Ltd.
Specialty Chemicals
match 147
58
39.4
27.0%
+8%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Yasons Chemex Care Ltd. operates in Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
49Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 6th percentile of the scored universe and 4th percentile within Industrials. Main check: financial discipline is weak at 20/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
6th percentile
overall median 67 · Industrials: 4th pctile, median 68 · SME: 6th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
20
weak · capital discipline
Results
53
watch · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Operating cash flow is negative at ₹-1 Cr.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸Only 0 years of positive FCF.
- ▸ROCE is low at 5.3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Yasons Chemex Care Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Copy of Newspaper Publication 8 Sep - Newspaper publication filed for 9th AGM notice, annual report 2025-26, book closure and e-voting details.
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.